معرفی
Tommaso de Marchi is an Associate Researcher and Postdoctoral Fellow at the Lund University Cancer Centre (LUCC) and the Medical Oncology department of Lund University. He actively contributes to interdisciplinary cancer research, particularly in proteogenomics, breast cancer, and radiosensitization.
- Key Affiliations: LUCC, Medical Oncology (Lund University), SweBCG-91-RT clinical trial team.
- Funding Sources: Marianne och Marcus Wallenbergs Stiftelse, Cancerfonden, Mrs. Berta Kamprad's Cancer Foundation.
His research spans cancer metabolism, proteomics, and precision oncology, with a focus on biomarker validation (e.g., PD-L1 assays) and therapeutic targets like PFKFB3. Recent work explores how ESR1 mutations influence cyclin-dependent kinase signaling in breast cancer.
Publications highlight collaborations across genetics, molecular biology, and clinical oncology, emphasizing tumor heterogeneity and metabolic pathways. He has contributed to 24 research outputs, including Nature Communications and Scientific Reports.
Scientific Recognition:
- 2014 AACR-Susan G. Komen® Scholar-in-Training Award
Mentorship & Activities:
- Co-supervisor for PhD research projects (e.g., computational epitope modeling)
- Examiner for summer projects (VMFX70-72, 2024)
- Organized workshops (e.g., Engineering Health Crossroads, 2023)
